GI Innovation, a Korean biotech company, announced its participation in the 2025 J.P. Morgan Healthcare Conference from Jan. 13-16 in San Francisco, Calif., U.S.

The company plans to engage in discussions regarding the technology transfer of its flagship pipelines, GI-101A and GI-102, which are T cell-based therapies that aim to treat hematologic cancers and solid tumors. T cell-based therapies, such as T cell engagers and CAR-T treatments, represent a groundbreaking modality in the $120 billion global hematologic cancer market.

With intense competition among major pharmaceutical companies, GI Innovation is aiming to position itself as a notable player in the field during the conference.

GI Innovation stressed that the company plans to meet with global pharmaceutical companies to explore licensing agreements, investment opportunities, and strategic collaborations.

The company has demonstrated the potential of GI-101A and GI-102 to enhance the efficacy of existing T cell-based therapies developed by leading global firms, supported by preclinical and early clinical data.

“GI-101A and GI-102 are showing significant promise in maximizing the effectiveness of T cell engagers and CAR-T therapies,” a company official said. “We expect meaningful progress in licensing discussions for hematologic cancer applications during the conference.”

In addition, GI Innovation has recently completed the administration of its GI-102 subcutaneous (SC) formulation in melanoma and gastric cancer patients. The company reported no safety or tolerability issues in patients and observed increased proliferation of immune cells compared to intravenous administration.

“Our recent clinical results validate the potential of SC formulations and the versatility of T cell-based modalities,” GI Innovation Chief Scientific Officer Jang Myoung-ho said. “With our platform's ability to stimulate immune cell proliferation, we are pursuing technology transfers tailored to specific indications.”

At this year’s conference, the company is determined to turn global pharmaceutical interest into tangible outcomes, Jang added.

Meanwhile, GI Innovation is also making strides in allergy treatments with GI-301 (YH35324), a candidate being developed in collaboration with Yuhan Corporation.

Yuhan has highlighted GI-301 as a potential successor to its blockbuster lung cancer drug, Leclaza. Clinical trials for GI-301 are progressing smoothly, and global licensing negotiations are underway.